SRX 251

Drug Profile

SRX 251

Alternative Names: API 251; SRX251

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Azevan Pharmaceuticals
  • Class Neuropsychotherapeutics
  • Mechanism of Action Vasopressin 1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Aggression
  • Discontinued Dysmenorrhoea

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Aggression in USA (PO)
  • 11 Jan 2010 SRX 251 is still in active development
  • 10 Dec 2009 Preclinical pharmacodynamics data presented at the 48th Annual Meeting of the American College of Neuropsychopharmacology (ACNP-2009)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top